Evidence map›Paper›PMID 40116570›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2025

Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid Arthritis.

Linda Mathsson Alm, Helga Westerlind, Isabel Gehring, Monika Hansson, Nasim Ghasemzadeh, Jessica Rojas-Restrepo, Saedis Saevarsdottir, Joe Sexton, Siri Lillegraven, Espen Haavardsholm and 8 more

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Genetic association betweenFrontiers in genetics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Linda Mathsson AlmUppsala University and Thermo Fisher Scientific, Uppsala, Sweden.
Helga WesterlindKarolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-3380-5342
Isabel GehringThermo Fisher Scientific, Freiburg, Germany.
Monika HanssonKarolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Nasim GhasemzadehThermo Fisher Scientific, Uppsala, Sweden.
Jessica Rojas-RestrepoThermo Fisher Scientific, Freiburg, Germany.
Saedis SaevarsdottirKarolinska Institutet, Stockholm, Sweden, and deCODE genetics/Amgen, University of Iceland, and Landspitali, the National University Hospital of Iceland, Reykjavik, Iceland.
Joe SextonDiakonhjemmet Hospital, Oslo, Norway.
Siri LillegravenDiakonhjemmet Hospital and University of Oslo, Oslo, Norway.ORCID https://orcid.org/0000-0003-3615-0134
Espen HaavardsholmDiakonhjemmet Hospital and University of Oslo, Oslo, Norway.
Bente GlintborgUniversity of Copenhagen, Copenhagen, Denmark, and DANBIO, The Danish Rheumatologic Biobank, and Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet, Glostrup, Denmark.ORCID https://orcid.org/0000-0002-8931-8482
Hilde Berner HammerDiakonhjemmet Hospital and University of Oslo, Oslo, Norway.
Tore K KvienDiakonhjemmet Hospital and University of Oslo, Oslo, Norway.ORCID https://orcid.org/0000-0002-8441-3093
Merete Lund HetlandUniversity of Copenhagen, Copenhagen, Denmark, and DANBIO, The Danish Rheumatologic Biobank, and Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet, Glostrup, Denmark.
Leonid PadyukovKarolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Swedish Rheumatology Quality Register Biobank Study Group (SRQb), The Danish Rheumatologic Biobank Study Group
Johan AsklingKarolinska Institutet, Stockholm, Sweden.
Caroline GrönwallKarolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-9111-5537

Funding

ERA PerMed ScandRA 2021-00757Innovationsfonden DenmarkNorges Forskningsråd 90825Swedish Research Council 2023-02497;2023-01827VINNOVA
6 · The paper itself

Abstract

objectiveRheumatoid arthritis (RA)-associated anticitrullinated protein antibodies (ACPAs) target various antigens by binding short citrulline amino acid motifs, resulting in heterogeneous ACPA profiles among patients. Here we analyzed ACPA patterns by recognized citrulline motifs in relation to the RA risk factors HLA-DRB1 shared epitope (SE) alleles and history of smoking.

methodsRheumatoid factor (RF) and anticyclic citrullinated peptide (CCP2) isotypes, 15 anti-Cit- and four anti-Carb/Acet-peptide-IgG, were centrally measured in 6,907 patients from five Scandinavian RA cohorts using fluoroenzyme immunoassay and a custom-made multiplex solid-phase microarray. HLA-DRB1 SE alleles were imputed from single-nucleotide polymorphism genotyping data.

resultsSingle-citrulline peptides derived from four multicitrulline peptides (Cit Fibα

conclusionAlthough citrulline-glycine motifs are prevalent ACPA targets, our data reveal that HLA SE alleles are primarily associated with ACPA to nonglycine citrulline motifs, providing insight in ACPA T cell dependance. Yet, the etiologic significance of ACPA targeting different protein structures remains unknown.

Indexed as

Anti-Citrullinated Protein AntibodiesArthritis, RheumatoidAutoantibodiesCitrullineGlycineHLA-DRB1 ChainsAdultAgedAllelesAmino Acid MotifsEpitopesFemaleHumansMaleMiddle AgedPeptides, CyclicAnti-Citrullinated Protein AntibodiesAutoantibodiesCitrullineEpitopesGlycineHLA-DRB1 ChainsPeptides, CyclicRheumatoid Factor

Identifiers

PMID40116570
PMCPMC12401802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.